[
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "In INTREPID 2013 and MERLOT 2016 the primary outcome was the number of pro re nata (PRN) ranibizumab injections administered over 52 weeks.Excluded studies\nSee 'Characteristics of excluded studies' table.Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Update searches run in May 2020 identified a further 1120 records (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Risk of bias in included studies\nFigure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Figure 2 and Figure 3 summarise the assessment of the risk of bias in included studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "We also noted an asymmetric funnel plot (Figure 4) possibly indicative of publication bias.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 569, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Blinding of outcome assessment (detection bias) Lesion size on fluorescein angiography\nLow risk\nQuote: \"Assessment of outcomes, including visual acuity, angiographic interpretation, and assessment of complications and adverse events, was performed in a masked fashion.\" Page 618\n\n\nIncomplete outcome data (attrition bias) All outcomes\nUnclear risk\nQuote: \"The overall complete follow‐up rate was 84.1% (85/101) (Table 1 and Figure 1). there was no significant difference between the two groups; the complete follow‐up rate was 88.2% (45/51) and 80.0% (40/50) in the treatment group and control group, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Page 2241, figure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  }
]